Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$193.98 USD
-2.44 (-1.24%)
Updated Sep 23, 2025 04:00 PM ET
After-Market: $193.81 -0.17 (-0.09%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About Return on Equity (TTM)
Ascendis Pharma A/S's return on equity, or ROE, is -16,574.15% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.95%. While this shows that ASND has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
ASND 193.98 -2.44(-1.24%)
Will ASND be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ASND based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ASND
Wall Street Analysts Believe Ascendis Pharma (ASND) Could Rally 29.83%: Here's is How to Trade
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
ASND: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock?
Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains?
Other News for ASND
Leerink Partners Reaffirms Their Buy Rating on Ascendis Pharma (ASND)
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in LB Pharmaceuticals Inc
Is ASND likely to continue higher? 50 Day Moving Average Support shows up after sliding 0.64%
Wedbush sees no threat to Ascendis’ Yorvipath from competitor data
Wedbush sees no threat to Ascendis' Yorvipath from competitor data